The neuroinflammation biomarker translocator protein (TSPO) plays a role in sucrose overconsumption in mice
|
Accepted Version
(PDF 106kB)
88672235. Available under License Creative Commons Attribution Non-commercial 4.0. |
Free-to-read version at publisher website
Description
Sugar overconsumption is a major cause of obesity. Existing pharmacotherapeutics for obesity have failed to stop the growing prevalence of this disease. Emerging research suggests that neuroinflammation mediates the pathogenesis of diet-induced obesity. Neuroinflammation has been implicated in many neuropathologies by measuring the expression of a neuroinflammatory biomarker – the translocator protein (TSPO). Etifoxine, a TSPO partial agonist and clinically used anxiolytic, is one of the few antipsychotic medications that does not cause weight gain. Given the proposed role of TSPO in anorexia and obesity, we hypothesized that etifoxine may have therapeutic potential in the treatment of sugar overconsumption. In this study, C57/BL6 mice consumed a 25% sucrose solution for 12 weeks starting at 6 weeks of age following common a common addiction consumption paradigm. After 6 and 12 weeks of sucrose consumption, two groups of 12 mice were treated with either intraperitoneal injections of etifoxine (20 mg/kg or 50 mg/kg) or the TSPO specific antagonist PK11195 (1mg/kg or 10 mg/kg). A single injection of 50 mg/kg etifoxine reduced sucrose consumption both 30 mins and 2 hrs into the drinking session, after 4 and 12 weeks of sucrose consumption. In contrast, PK11195 treatment did not alter sucrose consumption at either dose after 4 or 12 weeks of sucrose consumption. To assess if the effect seen from etifoxine is TSPO specific, a third group of 12 mice were pre-treated with 10 mg/kg PK11195 30 minutes prior to receiving a 50 mg/kg etifoxine injection. Pre-treatment with PK11195 blocked the consumption-reducing effect of etifoxine. Together, these results demonstrate that etifoxine acts through TSPO to reduce sucrose consumption in sucrose overconsuming mice. Given the well-documented safety profile of etifoxine, this study provides preliminary supporting evidence for its potential repurposing as an anti-obesity medication.
Impact and interest:
Citation counts are sourced monthly from Scopus and Web of Science® citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.
Full-text downloads:
Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.
ID Code: | 212253 | ||||||
---|---|---|---|---|---|---|---|
Item Type: | Contribution to conference (Abstract) | ||||||
Refereed: | No | ||||||
ORCID iD: |
|
||||||
Measurements or Duration: | 1 pages | ||||||
Pure ID: | 88672235 | ||||||
Divisions: | Current > QUT Faculties and Divisions > Faculty of Health Current > Schools > School of Clinical Sciences Current > Schools > School of Biomedical Sciences |
||||||
Copyright Owner: | Consult author(s) regarding copyright matters | ||||||
Copyright Statement: | This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au | ||||||
Deposited On: | 28 Jul 2021 16:57 | ||||||
Last Modified: | 03 Mar 2024 07:53 |
Export: EndNote | Dublin Core | BibTeX
Repository Staff Only: item control page